

Supplementary Information

Discovery of 2-amide-3-methylester thiophenes that target SARS-CoV-2 Mac1 and repress coronavirus replication, validating Mac1 as an anti-viral target

Sarah Wazir^{a,#}, Tomi A. O. Parviainen^{b,#}, Jessica J. Pfannenstiel^c, Men Thi Hoai Duong^a, Daniel Cluff^c, Sven T. Sowa^a, Albert Galera-Prat^a, Dana Ferraris^d, Mirko M. Maksimainen^a, Anthony R. Fehr^{c,*}, Juha P. Heiskanen^{b,*} & Lari Lehtiö^{a,*}

^aFaculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Finland

^bResearch Unit of Sustainable Chemistry, University of Oulu, P.O. Box 4300, FI-90014 Oulu, Finland

^cDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, United States of America.

^dMcDaniel College Department of Chemistry, 2 College Hill, Westminster, MD, USA.

[#]These authors contributed equally

*Address correspondence to arfehr@ku.edu, Juha.Heiskanen@oulu.fi or Lari.Lehtio@oulu.fi

CONTENT

Figure S1: IC₅₀ measurements of hit compounds.

Figure S2: Thermal shift assay.

Figure S3: Cell viability assays.

Figure S4: Comparison of Mac1 and MacroD2 crystal structures.

Table S1. Assay validation statistics.

Table S2. Hit validation and counter screening.

Table S3. Crystallography data and refinement statistics.

Figure S4-35. NMR spectra

Figure S36. HPLC chromatogram of **27** at 220nm detection wavelength.

Figure S37. HPLC chromatogram of **27** at 260nm detection wavelength.




Figure S1. Representative IC_{50} measurements of SARS-CoV-2 Mac1 for ADPr and initial hit compounds. Measurements were carried out in half-logarithmic dilution starting from 100 to 0.003 μ M for each curve. Negative control (containing no compound) was set one logarithmic unit below the lowest concentration. positive control (containing 200 μ M ADPr) was set one logarithmic unit above the highest concentration of the compound. Data is reported as mean \pm SD of four replicates.




Figure S2. Thermal shift assay of SARS-CoV-2 Mac1 for ADPr and initial hit compounds and the most potent compound **27**. (A) buffer control (green). ADPr (pink) (B) DMSO control (green). **1** (Red). **2** (Yellow). **3** (blue) (C) DMSO control (green). 30 μM **27** (brown), 60 μM **27** (purple). Each curve was measured three times, and a representative second derivative curve is shown.




Figure S3. Compound **27** does not affect the viability of mouse or human cell lines. (A-B) L929 (A), DBT (B) and Calu-3 (C) cells were treated with compound **27** at the indicated concentrations for 24 hours and then viability was measured by an MTT assay and normalized to the viability level of DMSO treated cells. The results in A and B are representative of 3 independent experiments, while the results in C are the combined results of 3 independent experiments. n=3.












Figure S4. Comparison of macrodomain crystal structures. (A) Superimposed SARS-CoV-2 Mac1 in complex with **27** (PDB: 8TV7, orange) and MacroD2 (PDB: 6Y4Y, blue). (B) SARS-CoV-2 Mac1 in complex with **27** and SARS-CoV Mac1 (PDB: 2ACF, cyan). Binding site residues and **27** is shown in sticks (orange).

Table S1. Assay validation statistics.

Statistical parameters	FRET assay
S/B	1.33 ± 0.03
S/N	22.04 ± 2.48
Z'	0.81 ± 0.02
Well-to-well CV (max/min. %)	$0.95 \pm 0.22 / 0.82 \pm 0.19$
Plate-to-plate CV (%)*	0.33
Day-to-day CV (%)*	2.55

*Calculated from Z' values.

Table S2. Hit validation and counter screening results with TNKS ARC4 assay.

ID	Figure	TNKS2 ARC4	NanoDSF ΔT_m °C	Inhibition % primary screening		IC ₅₀ (pIC ₅₀ ± SEM), n=3
				410 nm	430 nm	
1		NI*	1.0	60.5	73.3	14 μM (-4.85 ± 0.02)
2		NI	0.5	23.3	40.6	48 μM (-4.32 ± 0.02)
3		NI	1.0	29.2	31.8	110 μM (-3.96 ± 0.02)
4		NI	0.3	37.6	39.5	89 μM (-4.05 ± 0.01)
5		NI	0.1	32.3	30.5	45 μM (-4.34 ± 0.03)
6		NI	1.0	36.0	48.9	57 μM (-4.24 ± 0.03)
7		NI	0.1	64.5	59.7	NI
8		NI	0.3	75.5	77.5	57 μM (-4.26 ± 0.07)

*NI. no inhibition

Table S3. Data collection and refinement statistics for co-crystal structures.

Inhibitor (PDB id.)	1 (8TV6)	27 (8TV7)
Data collection		
Beamline	ID30A-1 ESRF	ID30A-1 ESRF
Wavelength (Å)	0.9655	0.9655
Space group	P1	P2 ₁ 2 ₁ 2 ₁
Unit cell dimensions		
<i>a</i> , <i>b</i> , <i>c</i> (Å)	30.20, 37.80, 64.10	38.0, 55.0, 71.9
α , β , γ (°)	95.60, 98.10, 90.40	90.0, 90.0, 90.0
Resolution range (Å)	37.58-1.74 (1.80-	43.72-1.50 (1.53-1.50)
Total no. of reflections	28635 (27298)	132023 (10008)
No. of unique reflections	27365 (1499)	25009 (1245)
Completeness (%)	95.4 (94.6)	99.9 (99.9)
<i>I</i> / σ (<i>I</i>)	7.3 (2.1)	9.8 (1.7)
CC1/2 (%)	99.0 (76.0)	99.7 (64.1)
<i>R</i> _{meas}	10.5 (46.7)	11.5 (92.5)
Model building and refinement		
R-factor	17.4	17.0
R-free	22.4	19.0
No. of atoms		
Protein	2580	1363
Ligands*	46	39
Water	220	146
RMSD		
Bonds (Å)	0.0075	0.0124
Angles (°)	0.1441	0.1590
Average <i>B</i> factors (Å ²)	23.03	17.39
Protein	15.27	12.94
Ligands*	31.11	15.44
Water	22.73	23.80
Ramachandran plot		
Favoured (%)	100	94
Allowed (%)	0.0	6.0
Outliers (%)	0.0	0.0

¹Values within parentheses refers to the highest resolution shell. *Inhibitor, PEG and glycerol molecules.

Figure S4. ^1H NMR spectrum of compound **9a** in CDCl_3 (-0.5–15 ppm).




Figure S5. ^1H NMR spectrum of compound **9b** in CDCl_3 (-0.5–15 ppm).




Figure S6. ^1H NMR spectrum of compound **9c** in CDCl_3 (-0.5–15 ppm).




Figure S7. ^1H NMR spectrum of compound **9d** in CDCl_3 (-0.5–15 ppm).




Figure S8. ^1H NMR spectrum of compound **9e** in d_6 -DMSO (-0.5–15 ppm).




Figure S9. ^1H NMR spectrum of compound **1r** in CDCl_3 (-0.5–15 ppm).




Figure S10. ^1H NMR spectrum of compound **1r** in d_6 -DMSO (-0.5–15 ppm).




Figure S11. ^{13}C NMR spectrum of compound **1r** in CDCl_3 (0–220 ppm)




Figure S12. ^1H NMR spectrum of compound **3r** in d_6 -DMSO (-0.5–15 ppm).




Figure S13. ^{13}C NMR spectrum of compound **3r** in CDCl_3 (0–220 ppm).




Figure S14. ^1H NMR spectrum of compound **10** in d_6 -DMSO (-0.5–15 ppm).




Figure S15. ^{13}C NMR spectrum of compound **10** in CDCl_3 (0–220 ppm).




Figure S16. ^1H NMR spectrum of compound **11** in CDCl_3 (-0.5–15 ppm).




Figure S17. ^{13}C NMR spectrum of compound **11** in CDCl_3 (0–220 ppm).




Figure S18. ^1H NMR spectrum of compound **15r** in d_6 -DMSO (-0.5–15 ppm).




Figure S19. ^{13}C NMR spectrum of compound **15r** in d_6 -DMSO (0–220 ppm).




Figure S20. ^1H NMR spectrum of compound **21** in d_6 -DMSO (-0.5–15 ppm).




Figure S21. ^{13}C NMR spectrum of compound **21** in CDCl_3 (0–220 ppm).




Figure S22. ^1H NMR spectrum of compound **22** in d_6 -DMSO (-0.5–15 ppm).




Figure S23. ^{13}C NMR spectrum of compound **22** in CDCl_3 (0–220 ppm).




Figure S24. ^1H NMR spectrum of compound **23** in d_6 -DMSO (-0.5–15 ppm).




Figure S25. ^{13}C NMR spectrum of compound **23** in CDCl_3 (0–220 ppm).




Figure S26. ^1H NMR spectrum of compound **24** in d_6 -DMSO (-0.5–15 ppm).




Figure S27. ^{13}C NMR spectrum of compound **24** in d_6 -DMSO (0–220 ppm).




Figure S28. ^1H NMR spectrum of compound **25** in CDCl_3 (-0.5–15 ppm).




Figure S29. ^{13}C NMR spectrum of compound **25** in CDCl_3 (0–220 ppm).




Figure S30. ^1H NMR spectrum of compound **26** in d_6 -DMSO (-0.5–15 ppm).




Figure S31. ^{13}C NMR spectrum of compound **26** in CDCl_3 (0–220 ppm).




Figure S32. ^1H NMR spectrum of compound **27** in d_6 -DMSO (-0.5–15 ppm).





Figure S33. ^{13}C NMR spectrum of compound **27** in CDCl_3 (0–220 ppm)



No.	(ppm)	(Hz)	Height	No.	(ppm)	(Hz)	Height	No.	(ppm)	(Hz)	Height
1	25.06	2521.8	0.1889	8	29.45	2962.7	0.1737	15	129.76	13055.5	0.1619
2	25.11	2526.2	0.1960	9	29.86	3004.5	0.1955	16	133.09	13390.7	0.1735
3	25.29	2544.5	0.1928	10	32.21	3240.7	0.2013	17	147.25	14815.4	0.1322
4	25.47	2562.1	0.1935	11	44.31	4457.7	0.2237	18	167.02	16804.2	0.1531
5	26.46	2661.9	0.1845	12	46.22	4649.9	0.2121	19	171.71	17276.6	0.1815
6	26.78	2694.9	0.1975	13	51.42	5173.7	0.2092	20	180.27	18137.8	0.1310
7	29.12	2929.7	0.1760	14	111.57	11225.2	0.1244				

Figure S34. ^1H NMR spectrum of compound **28** in CDCl_3 (-0.5–15 ppm).




Figure S35. ^{13}C NMR spectrum of compound **28** in CDCl_3 (0–220 ppm).






Figure S36. HPLC chromatogram of **27** at 220nm detection wavelength.



No.	tR	Peak Area (Y units*ms)	Area Percent	Width
1	8.45	36641216.000	0.739	0.650
2	12.32	16795072.000	0.339	0.179
3	13.23	4902276096.000	98.922	0.308

Figure S37. HPLC chromatogram of **27** at 260nm detection wavelength.



No.	tR	Peak Area (Y units*ms)	Area Percent	Width
1	9.18	4049237.000	0.156	0.456
2	9.85	7347586.500	0.283	0.790
3	12.36	6199013.500	0.238	0.287
4	13.23	2582017024.00	99.323	0.309